Business

St. Jude Medical stock falls after FDA report

Advertisement

Shares of St. Jude Medical fell after the FDA released a plant inspection report that found problems in the company’s testing and oversight of an electrical wire, or lead, that connects an implanted defibrillator to a patient’s heart. The FDA report raises the prospect of potential agency action. St. Jude executives have repeatedly insisted the lead is safe.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.